)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
BiomX (PHGE) investor relations material
BiomX Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Advanced phage-based clinical programs in cystic fibrosis (BX004) and diabetic foot osteomyelitis (BX211), with BX004 Phase 2b trial initiated and BX211 Phase 2 showing >40% wound size reduction and favorable safety profile.
BX004 Phase 1b/2a data published in Nature Communications, demonstrating ~500-fold bacterial reduction and no resistance in CF patients.
Completed acquisition of Adaptive Phage Therapeutics in March 2024, expanding the pipeline with two Phase 2 assets.
Discontinued atopic dermatitis program and paused prosthetic joint infection program to focus on CF and DFO.
High enthusiasm and accelerated enrollment for BX004 Phase 2b, with strong interest from patients, physicians, and partners.
Financial highlights
Cash and restricted cash totaled $15.2M as of June 30, 2025, down from $18M at year-end 2024, mainly due to operating activities.
Research and development expenses for Q2 2025 were $5.0M, down from $6.9M in Q2 2024, reflecting workforce reductions, lower rent, and increased grant funding.
General and administrative expenses were $2.4M for Q2 2025, down from $2.8M year-over-year, mainly due to reduced legal and professional fees.
Net loss for Q2 2025 was $6.0M, compared to net income of $4.5M in Q2 2024, primarily due to changes in fair value of warrants.
Net cash used in operating activities for the first half of 2025 was $14.8M, down from $22.6M in the same period of 2024.
Outlook and guidance
Cash runway expected to fund operations into Q1 2026; additional capital will be needed for longer-term operations.
Topline results from BX004 Phase 2b in CF expected in Q1 2026; FDA feedback on real-world evidence approach anticipated in H2 2025.
Planning for BX211 registrational study is underway, pending FDA discussions and continued collaboration with the US Defense Health Agency.
No significant product revenue expected in the next twelve months; continued losses anticipated.
What is the status of BX211 discussions with the Defense Health Agency?
What real-world evidence is being gathered for BX004 FDA feedback?
When is the expected timing for BX004 Phase IIb top line results?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BiomX earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage